[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
    "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index up 0.5% and the He",
    "url": "https://finnhub.io/api/news?id=d7a84725d89445c90d7228242101b93b9632e4861d7a4f88ad8045728c7c8baf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764795023,
      "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
      "id": 137678030,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index up 0.5% and the He",
      "url": "https://finnhub.io/api/news?id=d7a84725d89445c90d7228242101b93b9632e4861d7a4f88ad8045728c7c8baf"
    }
  },
  {
    "ts": null,
    "headline": "Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today",
    "summary": "Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 6.2% in the afternoon session after Morgan Stanley upgraded its rating on the stock to \"Overweight\" from \"Equal-Weight\" and increased its price target. The new price target was set at $516, a notable increase from the previous $438. The upgrade reflected the bank's more positive outlook on the potential within Vertex's kidney drug pipeline. The firm specifically highlighted two drug candidates, Pove and Inaxaplin, as key drive",
    "url": "https://finnhub.io/api/news?id=aaa5a3da01fdfa62a9e20be01d7cb77af2cbc1c9e5fe1c7176156bb06b7923ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764789089,
      "headline": "Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today",
      "id": 137678032,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 6.2% in the afternoon session after Morgan Stanley upgraded its rating on the stock to \"Overweight\" from \"Equal-Weight\" and increased its price target. The new price target was set at $516, a notable increase from the previous $438. The upgrade reflected the bank's more positive outlook on the potential within Vertex's kidney drug pipeline. The firm specifically highlighted two drug candidates, Pove and Inaxaplin, as key drive",
      "url": "https://finnhub.io/api/news?id=aaa5a3da01fdfa62a9e20be01d7cb77af2cbc1c9e5fe1c7176156bb06b7923ec"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Higher Wednesday Afternoon",
    "summary": "Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index and the Health Care Sel",
    "url": "https://finnhub.io/api/news?id=6ed6845038f0231f0f629ac32bb4fc9787623d5abf0312e67d297315a4ce51b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764786953,
      "headline": "Sector Update: Health Care Stocks Higher Wednesday Afternoon",
      "id": 137678033,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index and the Health Care Sel",
      "url": "https://finnhub.io/api/news?id=6ed6845038f0231f0f629ac32bb4fc9787623d5abf0312e67d297315a4ce51b6"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Vertex (VRTX) Up 2.7% Since Last Earnings Report?",
    "summary": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=f1abf79edc0eac89efce43691c8f7f7bd0d22c6af8fddebba15611d3fddee54c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764779417,
      "headline": "Why Is Vertex (VRTX) Up 2.7% Since Last Earnings Report?",
      "id": 137678034,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=f1abf79edc0eac89efce43691c8f7f7bd0d22c6af8fddebba15611d3fddee54c"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=94f7e63f6b7c41daaf1620c7af74c5fdac28f46e20e3f297e94c5d1db8fabf7a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764779400,
      "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 137684864,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=94f7e63f6b7c41daaf1620c7af74c5fdac28f46e20e3f297e94c5d1db8fabf7a"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals' Kidney Pipeline Seen as Growth Driver, Morgan Stanley Says",
    "summary": "Vertex Pharmaceuticals' (VRTX) kidney drug candidates Pove and Inaxaplin to significantly boost long",
    "url": "https://finnhub.io/api/news?id=374d93c586e51e0ae11e3973ab94021f37c6297636505dc219ae4a37cf94e5eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764777916,
      "headline": "Vertex Pharmaceuticals' Kidney Pipeline Seen as Growth Driver, Morgan Stanley Says",
      "id": 137672838,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals' (VRTX) kidney drug candidates Pove and Inaxaplin to significantly boost long",
      "url": "https://finnhub.io/api/news?id=374d93c586e51e0ae11e3973ab94021f37c6297636505dc219ae4a37cf94e5eb"
    }
  },
  {
    "ts": null,
    "headline": "Oracle initiated, Uber upgraded: Wall Street's top analyst calls",
    "summary": "Oracle initiated, Uber upgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=e6f035aa150c0c6a91f7123e35edfc87cbf7a1c8a0bec6df1ace16938f7d64e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764772507,
      "headline": "Oracle initiated, Uber upgraded: Wall Street's top analyst calls",
      "id": 137670877,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Oracle initiated, Uber upgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=e6f035aa150c0c6a91f7123e35edfc87cbf7a1c8a0bec6df1ace16938f7d64e6"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?",
    "summary": "VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum.",
    "url": "https://finnhub.io/api/news?id=ee8e874f54af59abc42468be57d34b71576760ee8599915605a61a06b1947d17",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764770460,
      "headline": "Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?",
      "id": 137671217,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum.",
      "url": "https://finnhub.io/api/news?id=ee8e874f54af59abc42468be57d34b71576760ee8599915605a61a06b1947d17"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript",
    "summary": "Vertex Pharmaceuticals Incorporated (VRTX) Citi Annual Global Healthcare Conference 2025 December 3, 2025 9:00 AM ESTCompany ParticipantsCharles Wagner -...",
    "url": "https://finnhub.io/api/news?id=608de6e7a9cd9270e4ad783d773eeffa84e1b37f890ea6aa6c40552a69a93963",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764761606,
      "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript",
      "id": 137671987,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals Incorporated (VRTX) Citi Annual Global Healthcare Conference 2025 December 3, 2025 9:00 AM ESTCompany ParticipantsCharles Wagner -...",
      "url": "https://finnhub.io/api/news?id=608de6e7a9cd9270e4ad783d773eeffa84e1b37f890ea6aa6c40552a69a93963"
    }
  },
  {
    "ts": null,
    "headline": "2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term",
    "summary": "Both can help drive excellent returns for patient, disciplined investors.",
    "url": "https://finnhub.io/api/news?id=41c915a0425e044a22d92515f71c276bc1ce6b805a9615a25845b5836f17e41e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764760500,
      "headline": "2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term",
      "id": 137671220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Both can help drive excellent returns for patient, disciplined investors.",
      "url": "https://finnhub.io/api/news?id=41c915a0425e044a22d92515f71c276bc1ce6b805a9615a25845b5836f17e41e"
    }
  }
]